I know this sort of coverage should not be taken as sole investment advice however, this offers a great breakdown of the promising pipeline at CHM, history and background for new investors.
This valuation is solely based on CHM 1101's potential for commercialisation. Cohort 4 at the highest dose 440 x 10(6) data has still not been released despite Phase 1B being initiated. The longer we wait usually the better it is, as patients have been able to see a more durable response. All data so far has indicated bucket loads of safety. We could get an update at any time really.
We now have the much anticipated CHM 2101 (CDH-17) finally in the clinic too so 2024 will have plenty of news flow.
Got a very good holding in multiple entities now to offset my early investment in the IPO. This was always going to be the long game, if the data equity in these sorts of biotechs keeps going up and the share pice goes down you know what to do. Buy more and put your feet up.
Good luck to all especially the patients.
Some great posts from some familiar faces in other biotech threads. @Shellbell@pfeifer1982
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)